Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz containing regimen.

Sara BettonteMattia BertonFelix StaderManuel BattegayCatia Marzolini

Published in: British journal of clinical pharmacology (2023)

Our simulations indicate that switching from an efavirenz-containing regimen to IM CAB/RPV does not put at risk of having a time window with suboptimal drug levels.

Keyphrases

hiv infected patients
antiretroviral therapy
hiv infected
molecular dynamics